Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
Aim. The analysis of the experience of using PCSK9 inhibitors (alirocumab) in patients with very high cardiovascular risk, аccording to long observations in real clinical practice.Material and methods. In study evaluated the data for 31 people (23 men and 8 women, the average age of those surveyed...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2023-03-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2893 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227505152557056 |
|---|---|
| author | S. Yu. Volkova L. A. Boyarskaya P. Yu. Toropygin I. A. Morozov E. A. Boyarskaya |
| author_facet | S. Yu. Volkova L. A. Boyarskaya P. Yu. Toropygin I. A. Morozov E. A. Boyarskaya |
| author_sort | S. Yu. Volkova |
| collection | DOAJ |
| description | Aim. The analysis of the experience of using PCSK9 inhibitors (alirocumab) in patients with very high cardiovascular risk, аccording to long observations in real clinical practice.Material and methods. In study evaluated the data for 31 people (23 men and 8 women, the average age of those surveyed was 59.4±5.8 years) of very high cardiovascular risk with atherogenic dyslipidemia and no achievement of the target lipid levels. Alirokumab was administered in a dose of 150 mg subcutaneously once every 2 weeks in the day hospital of a multidisciplinary clinic. The primary endpoint was reached the target level of low density lipoprotein cholesterol (HS-LDL) level and/or reduce HS-LDL levels by 50% or more. Liver tests, level of creatinine and glycemia were studied to assess safety; side effects studied/Results. The long-term use of alirocumab (on average 7,5±2,3 months) is well tolerated without adverse reactions and withdrawal syndrome, in the day hospital of a multidisciplinary clinic. 90% of patient have achieved either a target level of HS-LDL less than 1.4 mmol/l or a reduction in HS-LDL by 50% or more. The remaining third of patients achieved both target levels. It can be distinguished a group of patients with a good response to the medication, in the first months of administration of alirokumab.Conclusion. The results of conducting an efficiency assessment for use of the alirocumab in a dose of 150 mg subcutaneously within two weeks showed that this therapy has the high efficacy and good tolerability without any adverse reactions, in the day hospital of a multidisciplinary clinic. |
| format | Article |
| id | doaj-art-74dacb7e040d4586ada9bab050d1feba |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2023-03-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-74dacb7e040d4586ada9bab050d1feba2025-08-23T10:00:35ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532023-03-01191434910.20996/1819-6446-2023-02-012104Analysis of The Use of PCSK9 Inhibitors in Clinical PracticeS. Yu. Volkova0L. A. Boyarskaya1P. Yu. Toropygin2I. A. Morozov3E. A. Boyarskaya4Tyumen State Medical University; Tyumen Hospital West Siberian Medical Center FMBA of RussiaTyumen State Medical University; Tyumen Hospital West Siberian Medical Center FMBA of RussiaTyumen State Medical University; Tyumen Hospital West Siberian Medical Center FMBA of RussiaTyumen State Medical University; Tyumen Hospital West Siberian Medical Center FMBA of RussiaTyumen State Medical UniversityAim. The analysis of the experience of using PCSK9 inhibitors (alirocumab) in patients with very high cardiovascular risk, аccording to long observations in real clinical practice.Material and methods. In study evaluated the data for 31 people (23 men and 8 women, the average age of those surveyed was 59.4±5.8 years) of very high cardiovascular risk with atherogenic dyslipidemia and no achievement of the target lipid levels. Alirokumab was administered in a dose of 150 mg subcutaneously once every 2 weeks in the day hospital of a multidisciplinary clinic. The primary endpoint was reached the target level of low density lipoprotein cholesterol (HS-LDL) level and/or reduce HS-LDL levels by 50% or more. Liver tests, level of creatinine and glycemia were studied to assess safety; side effects studied/Results. The long-term use of alirocumab (on average 7,5±2,3 months) is well tolerated without adverse reactions and withdrawal syndrome, in the day hospital of a multidisciplinary clinic. 90% of patient have achieved either a target level of HS-LDL less than 1.4 mmol/l or a reduction in HS-LDL by 50% or more. The remaining third of patients achieved both target levels. It can be distinguished a group of patients with a good response to the medication, in the first months of administration of alirokumab.Conclusion. The results of conducting an efficiency assessment for use of the alirocumab in a dose of 150 mg subcutaneously within two weeks showed that this therapy has the high efficacy and good tolerability without any adverse reactions, in the day hospital of a multidisciplinary clinic.https://www.rpcardio.online/jour/article/view/2893pcsk9 inhibitoralirocumabhypercholesterolemiacardiovascular diseases |
| spellingShingle | S. Yu. Volkova L. A. Boyarskaya P. Yu. Toropygin I. A. Morozov E. A. Boyarskaya Analysis of The Use of PCSK9 Inhibitors in Clinical Practice Рациональная фармакотерапия в кардиологии pcsk9 inhibitor alirocumab hypercholesterolemia cardiovascular diseases |
| title | Analysis of The Use of PCSK9 Inhibitors in Clinical Practice |
| title_full | Analysis of The Use of PCSK9 Inhibitors in Clinical Practice |
| title_fullStr | Analysis of The Use of PCSK9 Inhibitors in Clinical Practice |
| title_full_unstemmed | Analysis of The Use of PCSK9 Inhibitors in Clinical Practice |
| title_short | Analysis of The Use of PCSK9 Inhibitors in Clinical Practice |
| title_sort | analysis of the use of pcsk9 inhibitors in clinical practice |
| topic | pcsk9 inhibitor alirocumab hypercholesterolemia cardiovascular diseases |
| url | https://www.rpcardio.online/jour/article/view/2893 |
| work_keys_str_mv | AT syuvolkova analysisoftheuseofpcsk9inhibitorsinclinicalpractice AT laboyarskaya analysisoftheuseofpcsk9inhibitorsinclinicalpractice AT pyutoropygin analysisoftheuseofpcsk9inhibitorsinclinicalpractice AT iamorozov analysisoftheuseofpcsk9inhibitorsinclinicalpractice AT eaboyarskaya analysisoftheuseofpcsk9inhibitorsinclinicalpractice |